Log in to save to my catalogue

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8215888

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a prospective, randomized trial involving patients with urothelial carcinoma who had undergone radical surgery, adjuvant nivolumab was compared with placebo. The median disease-free survival was 20.8 months with nivolumab and 10.8 months with placebo. Treatment-related adverse events of grade 3 or higher were noted in 17.9% of patients in the ni...

Alternative Titles

Full title

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8215888

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8215888

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2034442

How to access this item